Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPT NASDAQ:NVMI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyepoint Pharmaceuticals$12.93$13.46$5.45▼$19.11$1.08B1.76807,220 shs783,848 shsNVMINova$503.49$487.40$179.00▼$565.00$16.00B1.78384,414 shs214,493 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyepoint Pharmaceuticals0.00%+4.70%-6.47%-24.25%+127.64%NVMINova0.00%-1.11%-7.27%+13.78%+175.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyepoint Pharmaceuticals$12.93$13.46$5.45▼$19.11$1.08B1.76807,220 shs783,848 shsNVMINova$503.49$487.40$179.00▼$565.00$16.00B1.78384,414 shs214,493 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyepoint Pharmaceuticals0.00%+4.70%-6.47%-24.25%+127.64%NVMINova0.00%-1.11%-7.27%+13.78%+175.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyepoint Pharmaceuticals 3.00Buy$31.80145.94% UpsideNVMINova 2.82Moderate Buy$518.222.93% UpsideCurrent Analyst Ratings BreakdownLatest EYPT and NVMI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026NVMINova EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$600.005/15/2026NVMINova CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$520.00 ➝ $595.005/15/2026NVMINova BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$465.00 ➝ $600.005/14/2026NVMINova Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$520.00 ➝ $640.005/14/2026NVMINova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/14/2026NVMINova Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$494.005/14/2026NVMINova Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$500.00 ➝ $640.005/7/2026EYPTEyepoint Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$39.00 ➝ $37.004/21/2026EYPTEyepoint Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026NVMINova Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/10/2026NVMINova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyepoint Pharmaceuticals$7.61M142.38N/AN/A$2.75 per share4.70NVMINova$880.58M18.17$9.67 per share52.07$43.66 per share11.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyepoint Pharmaceuticals-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)NVMINova$259.22M$8.0262.7843.403.6929.21%21.77%12.56%8/6/2026 (Estimated)Latest EYPT and NVMI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026NVMINova$2.20$2.33+$0.13$2.04$227.02 million$235.31 million5/6/2026Q1 2026EYPTEyepoint Pharmaceuticals-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million3/4/2026Q4 2025EYPTEyepoint Pharmaceuticals-$0.78-$0.8143-$0.0343-$0.81$1.01 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/ANVMINovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyepoint PharmaceuticalsN/A6.666.63NVMINovaN/A1.581.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyepoint Pharmaceuticals99.41%NVMINova82.99%Insider OwnershipCompanyInsider OwnershipEYPTEyepoint Pharmaceuticals4.46%NVMINova1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyepoint Pharmaceuticals12083.84 million80.10 millionOptionableNVMINova1,61231.78 million31.47 millionOptionableEYPT and NVMI HeadlinesRecent News About These Companies42,804 Shares in Nova Ltd. $NVMI Purchased by Mizuho Markets Americas LLCMay 23 at 6:53 AM | marketbeat.comNova (NVMI) Q3 2025 Earnings Call TranscriptMay 21, 2026 | finance.yahoo.comYaniv Garty Sells 426 Shares of Nova (NASDAQ:NVMI) StockMay 21, 2026 | insidertrades.comNova Ltd. (NASDAQ:NVMI) Receives $518.22 Average Price Target from AnalystsMay 21, 2026 | americanbankingnews.comNova, Micron, Qualcomm, Amkor, and Allegro MicroSystems stocks trade up, what you need to knowMay 20, 2026 | msn.comHere’s Baron Opportunity Fund’s Updates on Nova Ltd (NVMI)May 20, 2026 | finance.yahoo.comNova to Participate in Upcoming Investor Conferences and EventsMay 18, 2026 | prnewswire.comWhat To Expect From Nova’s (NVMI) Q1 EarningsMay 16, 2026 | finance.yahoo.comNova Ltd. (NASDAQ:NVMI) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | marketbeat.comNova (NASDAQ:NVMI) Upgraded by Wall Street Zen to "Hold" RatingMay 16, 2026 | marketbeat.comA Look At Nova (NVMI) Valuation After Record Q1 2026 Beat And Upgraded OutlookMay 15, 2026 | finance.yahoo.comNova: The Stock Is Expensive, But Execution Remains StrongMay 15, 2026 | seekingalpha.comCompany News for May 15, 2026May 15, 2026 | finance.yahoo.comNova Ltd (NVMI) Q1 2026 Earnings Call Highlights: Record Revenue and Market Share Gains Amid ...May 15, 2026 | finance.yahoo.comPhoenix Financial Ltd. Has $167.12 Million Stock Position in Nova Ltd. $NVMIMay 15, 2026 | marketbeat.comNova (NASDAQ:NVMI) Price Target Raised to $640.00 at Needham & Company LLCMay 15, 2026 | americanbankingnews.comNova (NASDAQ:NVMI) Sets New 52-Week High After Earnings BeatMay 15, 2026 | americanbankingnews.comNova (NASDAQ:NVMI) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPSMay 14, 2026 | marketbeat.comNova Sets June 18, 2026 Annual Meeting to Vote on Board Slate, CEO Pay and Auditor ReappointmentMay 14, 2026 | tipranks.comHow The Nova (NasdaqGS:NVMI) Narrative Is Shifting With Metrology Growth And Valuation DebatesMay 14, 2026 | uk.finance.yahoo.comNova Shares Rise After Record Quarter and Strong OutlookMay 14, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEYPT and NVMI Company DescriptionsEyepoint Pharmaceuticals NASDAQ:EYPT$12.93 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.92 -0.01 (-0.08%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Nova NASDAQ:NVMI$503.49 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$499.44 -4.05 (-0.81%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nova Ltd. designs, develops, produces, and sells process control systems used in the manufacture of semiconductors in Israel, Taiwan, the United States, China, Korea, and internationally. Its product portfolio includes a set of metrology platforms for dimensional, films, and materials and chemical metrology measurements for process control for various semiconductor manufacturing process steps, including lithography, etch, chemical mechanical planarization, deposition, electrochemical plating, and advanced packaging. The company serves various sectors of the integrated circuit manufacturing industry, including logic, foundries, and memory manufacturers, as well as process equipment manufacturers. Nova Ltd. was formerly known as Nova Measuring Instruments Ltd. and changed its name to Nova Ltd. in July 2021. Nova Ltd. was incorporated in 1993 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
